Literature DB >> 20722758

Osteopontin is up-regulated and associated with neutrophil and macrophage infiltration in glioblastoma.

Nadia A Atai1, Manju Bansal, Cheungh Lo, Joost Bosman, Wikky Tigchelaar, Klazien S Bosch, Ard Jonker, Philip C De Witt Hamer, Dirk Troost, Christopher A McCulloch, Vincent Everts, Cornelis J F Van Noorden, Jaro Sodek.   

Abstract

Osteopontin (OPN) is a glycophosphoprotein with multiple intracellular and extracellular functions. In vitro, OPN enhances migration of mouse neutrophils and macrophages. In cancer, extracellular OPN facilitates migration of cancer cells via its RGD sequence. The present study was designed to investigate whether osteopontin is responsible for neutrophil and macrophage infiltration in human cancer and in particular in glioblastoma. We found that in vitro mouse neutrophil migration was RGD-dependent. In silico, we found that the OPN gene was one of the 5% most highly expressed genes in 20 out of 35 cancer microarray data sets in comparison with normal tissue in at least 30% of cancer patients. In some types of cancer, such as ovarian cancer, lung cancer and melanoma, the OPN gene was one of those with the highest expression levels in at least 90% of cancer patients. In glioblastoma, the most invasive type of brain tumours/glioma, but not in lower grades of glioma it was one of the 5% highest expressed genes in 90% of patients. In situ, we found increased protein levels of OPN in human glioblastoma versus normal human brain confirming in silico results. OPN protein expression was co-localized with neutrophils and macrophages. In conclusion, OPN in tumours not only induces migration of cancer cells but also of leucocytes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20722758      PMCID: PMC3015073          DOI: 10.1111/j.1365-2567.2010.03335.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  97 in total

1.  Radiological assessment of osteo-arthrosis.

Authors:  J H KELLGREN; J S LAWRENCE
Journal:  Ann Rheum Dis       Date:  1957-12       Impact factor: 19.103

2.  Polarization and directed migration of murine neutrophils is dependent on cell surface expression of CD44.

Authors:  Per Alstergren; Baoqian Zhu; Michael Glogauer; Michael Glougauer; Tak W Mak; Richard P Ellen; Jaro Sodek
Journal:  Cell Immunol       Date:  2004 Sep-Oct       Impact factor: 4.868

3.  Chromosomal aberrations and gene expression profiles in non-small cell lung cancer.

Authors:  E Dehan; A Ben-Dor; W Liao; D Lipson; H Frimer; S Rienstein; D Simansky; M Krupsky; P Yaron; E Friedman; G Rechavi; M Perlman; A Aviram-Goldring; S Izraeli; M Bittner; Z Yakhini; N Kaminski
Journal:  Lung Cancer       Date:  2007-01-25       Impact factor: 5.705

4.  Two subclasses of lung squamous cell carcinoma with different gene expression profiles and prognosis identified by hierarchical clustering and non-negative matrix factorization.

Authors:  Kentaro Inamura; Takeshi Fujiwara; Yujin Hoshida; Takayuki Isagawa; Michael H Jones; Carl Virtanen; Miyuki Shimane; Yukitoshi Satoh; Sakae Okumura; Ken Nakagawa; Eiju Tsuchiya; Shumpei Ishikawa; Hiroyuki Aburatani; Hitoshi Nomura; Yuichi Ishikawa
Journal:  Oncogene       Date:  2005-10-27       Impact factor: 9.867

5.  Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer.

Authors:  Azizbek Ramankulov; Michael Lein; Glen Kristiansen; Stefan A Loening; Klaus Jung
Journal:  Prostate       Date:  2007-02-15       Impact factor: 4.104

6.  Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression.

Authors:  Sooryanarayana Varambally; Jianjun Yu; Bharathi Laxman; Daniel R Rhodes; Rohit Mehra; Scott A Tomlins; Rajal B Shah; Uma Chandran; Federico A Monzon; Michael J Becich; John T Wei; Kenneth J Pienta; Debashis Ghosh; Mark A Rubin; Arul M Chinnaiyan
Journal:  Cancer Cell       Date:  2005-11       Impact factor: 31.743

7.  Osteopontin expression and distribution in human carcinomas.

Authors:  L F Brown; A Papadopoulos-Sergiou; B Berse; E J Manseau; K Tognazzi; C A Perruzzi; H F Dvorak; D R Senger
Journal:  Am J Pathol       Date:  1994-09       Impact factor: 4.307

8.  Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury.

Authors:  Kazuaki Nishijima; Yin-Shan Ng; Lichun Zhong; John Bradley; William Schubert; Nobuo Jo; Jo Akita; Steven J Samuelsson; Gregory S Robinson; Anthony P Adamis; David T Shima
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307

9.  [Investigation of the new QNR-based mechanism of quinolone resistance among enterobacterial strains isolated in Henri-Mondor hospital 2002-2005].

Authors:  S Honoré; C Lascols; D Malin; R Targaouchi; V Cattoir; P Legrand; C-J Soussy; E Cambau
Journal:  Pathol Biol (Paris)       Date:  2006-02-13

Review 10.  Role of osteopontin in regulating hepatic inflammatory responses and toxic liver injury.

Authors:  Shashi K Ramaiah; Susan Rittling
Journal:  Expert Opin Drug Metab Toxicol       Date:  2007-08       Impact factor: 4.481

View more
  36 in total

Review 1.  Role of osteopontin in the pathophysiology of cancer.

Authors:  Lalita A Shevde; Rajeev S Samant
Journal:  Matrix Biol       Date:  2014-03-19       Impact factor: 11.583

2.  Association of osteopontin expression with the prognosis of glioma patient: a meta-analysis.

Authors:  Mingfei Zhao; Hangdi Xu; Feng Liang; Jiliang He; Jianmin Zhang
Journal:  Tumour Biol       Date:  2014-09-30

3.  Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma.

Authors:  Kyu Sang Lee; Kyoungyul Lee; Sumi Yun; Seyoung Moon; Yujun Park; Jung Ho Han; Chae-Yong Kim; Hye Seung Lee; Gheeyoung Choe
Journal:  J Neurooncol       Date:  2017-11-16       Impact factor: 4.130

4.  The role of osteopontin expression in melanoma progression.

Authors:  Timea Kiss; Szilvia Ecsedi; Laura Vizkeleti; Viktoria Koroknai; Gabriella Emri; Nora Kovács; Roza Adany; Margit Balazs
Journal:  Tumour Biol       Date:  2015-05-07

5.  Identification of therapeutic targets for glioblastoma by network analysis.

Authors:  D Friedmann-Morvinski; V Bhargava; S Gupta; I M Verma; S Subramaniam
Journal:  Oncogene       Date:  2015-05-11       Impact factor: 9.867

Review 6.  Inflammatory stress and sarcomagenesis: a vicious interplay.

Authors:  Jürgen Radons
Journal:  Cell Stress Chaperones       Date:  2013-08-27       Impact factor: 3.667

7.  Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer.

Authors:  Federico Carbone; Francesco Grossi; Aldo Bonaventura; Alessandra Vecchié; Silvia Minetti; Nicholas Bardi; Edoardo Elia; Anna Maria Ansaldo; Daniele Ferrara; Erika Rijavec; Maria Giovanna Dal Bello; Federica Biello; Giovanni Rossi; Marco Tagliamento; Angela Alama; Simona Coco; Paolo Spallarossa; Franco Dallegri; Carlo Genova; Fabrizio Montecucco
Journal:  Clin Exp Metastasis       Date:  2019-08-02       Impact factor: 5.150

8.  Osteopontin increases heme oxygenase-1 expression and subsequently induces cell migration and invasion in glioma cells.

Authors:  Dah-Yuu Lu; Wei-Lan Yeh; Ssu-Ming Huang; Chih-Hsin Tang; Hsiao-Yun Lin; Shao-Jiun Chou
Journal:  Neuro Oncol       Date:  2012-10-16       Impact factor: 12.300

9.  Thrombin-cleaved fragments of osteopontin are overexpressed in malignant glial tumors and provide a molecular niche with survival advantage.

Authors:  Yasuto Yamaguchi; Zhifei Shao; Shadi Sharif; Xiao-Yan Du; Timothy Myles; Milton Merchant; Griffith Harsh; Michael Glantz; Lawrence Recht; John Morser; Lawrence L K Leung
Journal:  J Biol Chem       Date:  2012-11-30       Impact factor: 5.157

10.  Osteopontin level and promoter polymorphism in patients with metastatic breast cancer.

Authors:  M A Elbaiomy; T Akl; R Elhelaly; W El-Beshbishi; M S El Ghonemy; R Elzehery
Journal:  Curr Oncol       Date:  2020-10-01       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.